The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move.

Immuno-oncology (IO) drugs used to treat cancer boost the immune response to a disease. Immunotherapy treatment uses a person’s immune system to fight cancer with monoclonal antibodies ...

Taking the 'GLP-1 receptor agonist' class of anti-obesity drugs is related with lower rates of post-surgery complications in people with diabetes, according to a study. Patients taking the anti ...

The revised definition, published in The Lancet Diabetes & Endocrinology 1 on 14 January, focuses on how excess body fat, a ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

Please provide your email address to receive an email when new articles are posted on . Anti-obesity medication users achieved more weight loss vs. nonusers. There were no differences in weight ...

Participants who switched to older anti-obesity drugs after GLP-1 therapy lost about 25% of their weight from baseline, researchers found. Participants mostly received metformin following GLP-1s.

In our state, obesity costs $37.3 billion in reduced economic activity, or 1.8% of New York’s GDP. It also has a $5.2 billion impact on the state budget, including $3 billion less in tax revenue ...

Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions. David Ricks, the chair and chief ...

Obesity is associated with an increased risk of VTE, and it has been postulated that standard prophylactic LMWH doses may be insufficient to prevent VTE or achieve suggested anti-factor Xa target ...

Senator Bernie Sanders (I-VT), for example, stated that “unless Medicare demands that Novo Nordisk and Eli Lilly substantially reduce the prices for these anti-obesity drugs, Medicare premiums ...